Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2024

01-04-2024 | Ruxolitinib | Case report

Ruxolitinib

Haemorrhage

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Kiladjian J-J, et al. Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study. Blood 140 (Suppl.) : 3968-3969, Nov 2022. Available from: URL: https://dx.doi.org/10.1182/blood-2022-156628 [abstract]
Metadata
Title
Ruxolitinib
Haemorrhage
Publication date
01-04-2024
Publisher
Springer International Publishing
Keyword
Ruxolitinib
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56565-5

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Multiple drugs

Case report

Darunavir/Fluticasone-propionate/Ritonavir interaction

Case report

Alemtuzumab/cyclophosphamide/pentostatin

Case report

Empagliflozin

Case report

Multiple drugs

Case report

Denosumab